Seminars in Radiation Oncology
Volume 17, Issue 1 , Pages 53-61 , January 2007

Considerations in Treatment Planning for Esophageal Cancer

  • Theodore S. Hong, MD

      Affiliations

    • Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA.
    • ,
  • Elizabeth M. Crowley, MS

      Affiliations

    • Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA.
    • ,
  • Joseph Killoran, PhD

      Affiliations

    • Department of Radiation Oncology, Dana Farber Cancer Institute, Brigham and Women’s Hospital, Boston, MA.
    • ,
  • Harvey J. Mamon, MD, PhD

      Affiliations

    • Department of Radiation Oncology, Dana Farber Cancer Institute, Brigham and Women’s Hospital, Boston, MA.
    • Corresponding Author InformationAddress reprint requests to Harvey J. Mamon, MD, PhD, Department of Radiation Oncology, Dana Farber Cancer Institute, Brigham and Women’s Hospital, 75 Francis Street, L2, Boston, MA 02115.

References 

  1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8–29
  2. Hulscher JB, van Sandick JW, de Boer AG, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002;347:1662–1669
  3. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: A randomised controlled trial. Lancet. 2002;359:1727–1733
  4. Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;335:462–467
  5. Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326:1593–1598
  6. Hosch SB, Stoecklein NH, Pichlmeier U, et al. Esophageal cancer: The mode of lymphatic tumor cell spread and its prognostic significance. J Clin Oncol. 2001;19:1970–1975
  7. Minsky BD, Neuberg D, Kelsen DP, et al. Final report of Intergroup Trial 0122 (ECOG PE-289, RTOG 90-12): Phase II trial of neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys. 1999;43:517–523
  8. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20:1167–1174
  9. Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 1997;337:161–167
  10. Urba SG, Orringer MB, Turrisi A, et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001;19:305–313
  11. Krasna M, Tepper JE, Niedzwiecki D, et al. Trimodality therapy is superior to surgery alone in esophageal cancer: Results of CALGB 9781. 2006;Paper presented at: ASCO 2006 Gastrointestinal Cancers Symposium, San Francisco, California, January 26-28
  12. Kwa SL, Theuws JC, Wagenaar A, et al. Evaluation of two dose-volume histogram reduction models for the prediction of radiation pneumonitis. Radiother Oncol. 1998;48:61–69
  13. Yorke ED, Jackson A, Rosenzweig KE, et al. Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2002;54:329–339
  14. Oetzel D, Schraube P, Hensley F, et al. Estimation of pneumonitis risk in three-dimensional treatment planning using dose-volume histogram analysis. Int J Radiat Oncol Biol Phys. 1995;33:455–460
  15. Graham MV, Purdy JA, Emami B, et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 1999;45:323–329
  16. Hernando ML, Marks LB, Bentel GC, et al. Radiation-induced pulmonary toxicity: A dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys. 2001;51:650–659
  17. Lingos TI, Recht A, Vicini F, et al. Radiation pneumonitis in breast cancer patients treated with conservative surgery and radiation therapy. Int J Radiat Oncol Biol Phys. 1991;21:355–360
  18. Law S, Wong KH, Kwok KF, et al. Predictive factors for postoperative pulmonary complications and mortality after esophagectomy for cancer. Ann Surg. 2004;240:791–800
  19. Wang SL, Liao Z, Vaporciyan AA, et al. Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys. 2006;64:692–699
  20. Chandra A, Guerrero TM, Liu HH, et al. Feasibility of using intensity-modulated radiotherapy to improve lung sparing in treatment planning for distal esophageal cancer. Radiother Oncol. 2005;77:247–253
  21. Early Breast Cancer Trialists’ Collaborative Group. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: An overview of the randomised trials. Lancet. 2000;355:1757–1770
  22. Ng AK, Bernardo MP, Weller E, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin’s disease treated at age 50 or younger. J Clin Oncol. 2002;20:2101–2108
  23. Eriksson F, Gagliardi G, Liedberg A, et al. Long-term cardiac mortality following radiation therapy for Hodgkin’s disease: Analysis with the relative seriality model. Radiother Oncol. 2000;55:153–162
  24. Pera M, Manterola C, Vidal O, et al. Epidemiology of esophageal adenocarcinoma. J Surg Oncol. 2005;92:151–159
  25. Lavrenkov K, Partridge M, Cook G, et al. Positron emission tomography for target volume definition in the treatment of non-small cell lung cancer. Radiother Oncol. 2005;77:1–4
  26. Nishioka T, Shiga T, Shirato H, et al. Image fusion between 18FDG-PET and MRI/CT for radiotherapy planning of oropharyngeal and nasopharyngeal carcinomas. Int J Radiat Oncol Biol Phys. 2002;53:1051–1057
  27. Leong T, Everitt C, Yuen K, et al. A prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer. Radiother Oncol. 2006;78:254–261
  28. Moureau-Zabotto L, Touboul E, Lerouge D, et al. Impact of CT and 18F-deoxyglucose positron emission tomography image fusion for conformal radiotherapy in esophageal carcinoma. Int J Radiat Oncol Biol Phys. 2005;63:340–345
  29. Konski A, Doss M, Milestone B, et al. The integration of 18-fluoro-deoxy-glucose positron emission tomography and endoscopic ultrasound in the treatment-planning process for esophageal carcinoma. Int J Radiat Oncol Biol Phys. 2005;61:1123–1128
  30. Vrieze O, Haustermans K, De Wever W, et al. Is there a role for FGD-PET in radiotherapy planning in esophageal carcinoma?. Radiother Oncol. 2004;73:269–275
  31. van Westreenen HL, Heeren PA, Jager PL, et al. Pitfalls of positive findings in staging esophageal cancer with F-18-fluorodeoxyglucose positron emission tomography. Ann Surg Oncol. 2003;10:1100–1105
  32. Lowe VJ, Booya F, Fletcher JG, et al. Comparison of positron emission tomography, computed tomography, and endoscopic ultrasound in the initial staging of patients with esophageal cancer. Mol Imaging Biol. 2005;7:422–430
  33. Shrikanthan S, Aydin A, Dhurairaj T, et al. Intense esophageal FDG activity caused by Candida infection obscured the concurrent primary esophageal cancer on PET imaging. Clin Nucl Med. 2005;30:695–697
  34. Bural GG, Kumar R, Mavi A, et al. Reflux esophagitis secondary to chemotherapy detected by serial FDG-PET. Clin Nucl Med. 2005;30:182–183
  35. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001;19:3058–3065
  36. Downey RJ, Akhurst T, Ilson D, et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: Results of a prospective trial. J Clin Oncol. 2003;21:428–432
  37. Song SY, Kim JH, Ryu JS, et al. FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer. Int J Radiat Oncol Biol Phys. 2005;63:1053–1059
  38. Wieder HA, Beer AJ, Lordick F, et al. Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction. J Nucl Med. 2005;46:2029–2034
  39. Westerterp M, van Westreenen HL, Reitsma JB, et al. Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy–systematic review. Radiology. 2005;236:841–851
  40. Hong D, Lunagomez S, Kim EE, et al: Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma. Cancer 104:1620-1626, 15
  41. Jarritt P, Hounsell A, Carson K, et al. Use of combined PET/CT images for radiotherapy planning: Initial experiences in lung cancer. Br J Radiol. 2005;28(suppl):S33–S40
  42. Mell LK, Roeske JC, Mundt AJ. A survey of intensity-modulated radiation therapy use in the United States. Cancer. 2003;98:204–211
  43. Wu Q, Mohan R, Morris M, et al. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas (I: Dosimetric results). Int J Radiat Oncol Biol Phys. 2003;56:573–585
  44. Fu WH, Wang LH, Zhou ZM, et al. Comparison of conformal and intensity-modulated techniques for simultaneous integrated boost radiotherapy of upper esophageal carcinoma. World J Gastroenterol. 2004;10:1098–1102

PII: S1053-4296(06)00066-X

doi: 10.1016/j.semradonc.2006.09.001

Seminars in Radiation Oncology
Volume 17, Issue 1 , Pages 53-61 , January 2007

Article Tools

* Image Usage & Resolution